Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel and XPartners in connection with the acquisition of Vibroakustik
Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of Vibroakustik

February 13, 2024 M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Vibroakustik Sverige AB (”Vibroakustik”).

Vibroakustik is a consulting company specialised in reducing environmental impact and improving the working environment through advanced measurement and analysis services. Within environmental impact, Vibroakustik takes a holistic approach to environmental challenges, with an emphasis on risk analysis, inspections and measurement and analysis of noise and vibration in order to ensure that major construction and infrastructure projects comply with environmental requirements and that the adverse impact on the environment is minimised.

Vinge’s team consisted of responsible partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Gustav Persson, Sara Passandideh and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025